Black Titan Corporation (BTTC)
BTTC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-07-31, https://www.sec.gov/Archives/edgar/data/2034400/000149315226050502/0001493152-26-050502-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2026-07-31.
Profile
| Field | Value |
|---|---|
| Ticker | BTTC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Malaysia |
| IPO year | Not reported by the screener |
| SEC CIK | 0002034400 |
| SEC industry code | Services-Computer Programming Services |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $2.2M |
| Net income | -$5.8M |
| Operating income | -$5.7M |
| Net margin | -268.1% |
| Operating margin | -262.1% |
| Revenue growth | -18.8% |
| Cash | $2.9M |
| Total assets | $7.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 20-F 2026-11-06 |
| Cash and burn | $2.9M cash; operating cash flow -$1.3M a quarter. | Report 2026-07-31 |
| Shares outstanding | 14,996,962 (2026-11-02); 7,723,620 a year earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Guangdong Prouden CPAs GP, Guangzhou, China | PCAOB Form AP 2026-11-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-07-31 | $2.2M | -$5.8M | -$5.0M | $2.9M | $490K | $2.2M | 20-F 2026-11-06 |
| FY 2025 2025-07-31 | $2.7M | $210K | $394K | $575K | $20K | $2.7M | 20-F 2026-11-06 |
| FY 2024 2024-07-31 | $2.1M | $153K | $192K | $684K | No debt tags | $2.1M | 20-F 2026-11-06 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-18 |
| Latest annual report | 20-F | 2026-11-06 |
| Latest quarterly / interim | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 84 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.9% |
| 1 month | -27.9% |
| 3 months | -50.3% |
| Year to date | -81.1% |
| 1 year | -90.2% |
| From 52-week high | -92.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
| SNTI | Senti Biosciences Holdings Inc. | $0.1360 | -2.86% | $5.2M |
| VIVS | VivoSim Labs Inc. | $0.1237 | -2.68% | $2.5M |
| CLDI | Calidi Biotherapeutics Inc. | $0.6023 | -3.15% | $2.2M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier